Theriva Biologics
TOVX
38 hedge funds and large institutions have $51.9M invested in Theriva Biologics in 2015 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 4 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
37% more capital invested
Capital invested by funds: $37.9M → $51.9M (+$14M)
31% more funds holding
Funds holding: 29 → 38 (+9)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$964K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$696K |
| 3 |
CIC
Carnegie Investment Counsel
Pepper Pike,
Ohio
|
+$607K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$214K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.84M |
| 2 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$22K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$18K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$17.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.9K |
TOVX Hedge Fund Activity: Q1 2015 in Review
38 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2015, worth a combined $51.9M — up 37% from $37.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TOVX positions and 4 closed out — a net gain of 9 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $964K. The largest seller was Great Point Partners, exiting entirely with an estimated $5.84M sold.
- 38 institutional investors held Theriva Biologics (TOVX) as of Q1 2015, up from 29 in Q4 2014.
- Funds reported $51.9M of Theriva Biologics stock for Q1 2015, up 37% quarter-over-quarter.
- 13 funds opened new Theriva Biologics positions in Q1 2015 and 4 closed out, a net change of +9 holders.
- The largest Theriva Biologics buyer in Q1 2015 was Vanguard Group, an estimated $964K added.
- The largest Theriva Biologics seller in Q1 2015 was Great Point Partners, an estimated $5.84M sold.
Based on aggregated 13F filings for Q1 2015.